Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis

Documenti analoghi

• Response to Letters Regarding “Comedications Associated with Immune‐Related Adverse Events from Immune‐Checkpoint Inhibitors”
  di: Léonard Laurent, et al.
  Pubblicazione: (2025)
• Major Adverse Cardiac Events with Ondansetron: A Systematic Review
  di: Michael Cristian Garcia, et al.
  Pubblicazione: (2025)
• A Consideration of Exploratory Approaches to Comedications Associated With Immune‐Related Adverse Events during Immune Checkpoint Inhibitor Therapy
  di: Yoshihiro Noguchi, et al.
  Pubblicazione: (2025)
• Challenging the Detection of Comedication Interactions Related to Immune‐Related Adverse Events Using Spontaneous Reporting Systems
  di: Yuki Nakano
  Pubblicazione: (2025)
• Real‐World Safety of JAK Inhibitors in Skin Immune‐Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study
  di: Teng‐Li Lin, et al.
  Pubblicazione: (2026)